What is OpenEvidence?
OpenEvidence operates as a leading medical information platform tailored for healthcare professionals. Originating from the Mayo Clinic Platform Accelerate program, the company has garnered attention from prestigious institutions like the New England Journal of Medicine AI. Its services are utilized by medical professionals across the United States, offering unrestricted access to its resources. The platform's development from a foundational seed round to subsequent, larger investment rounds signifies its evolution into a scalable enterprise solution.
How much funding has OpenEvidence raised?
OpenEvidence has raised a total of $880M across 5 funding rounds:
Seed
$20M
Multiple Rounds
$610M
Series D
$250M
Seed (2021): $20M, investors not publicly disclosed
Series B (2025): $210M led by Kleiner Perkins, Coatue, Thrive, Conviction, Google, and Sequoia Capital
Other Financing Round (2025): $200M supported by Thrive Capital, Coatue, Kleiner Perkins, Sequoia Capital, Google, and Blackstone
Series C (2025): $200M featuring Sequoia Capital, Kleiner Perkins, GV, and Thrive Capital
Series D (2026): $250M backed by Thrive Capital and DST Global
Key Investors in OpenEvidence
Kleiner Perkins
Kleiner Perkins is a venture capital firm based in Menlo Park, specializing in early and growth-stage technology and life science companies, providing capital and operational support from seed through IPO or acquisition.
Coatue
Coatue Management is an employee-owned hedge fund sponsor that invests in public equity and private equity globally, with a focus on equity-related securities.
Thrive
Thrive, originally an IT services firm, has evolved into a leading NextGen MSP/MSSP, delivering global cybersecurity, Cloud, and digital transformation Managed Services, supported by strategic investments.
What's next for OpenEvidence?
With its latest major strategic investment, OpenEvidence is poised for accelerated growth and enhanced service offerings. The substantial capital infusion, particularly in its Series B and subsequent rounds, suggests a strategic focus on expanding its market reach, refining its technological infrastructure, and potentially exploring new avenues for data dissemination and analysis. The company's consistent access to significant funding from prominent venture capital firms indicates strong investor confidence in its business model and its potential to disrupt the medical information landscape. Future developments are likely to center on deepening its integration within healthcare systems and further solidifying its role as a critical resource for medical professionals.
See full OpenEvidence company page
